Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?Zacks Investment Research • 01/10/24
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio ProgramsBusiness Wire • 01/08/24
Prothena Reports Third Quarter 2023 Financial Results and Business HighlightsBusiness Wire • 11/02/23
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentInvestors Business Daily • 10/26/23
Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/26/23
Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/17/23
Prothena Reports Second Quarter 2023 Financial Results and Business HighlightsBusiness Wire • 08/03/23
Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)Business Wire • 07/17/23
Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)Business Wire • 07/11/23
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau AntibodyBusiness Wire • 07/10/23
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with BirtamimabBusiness Wire • 06/27/23